Abstract:Objectives: Non-alcoholic steatohepatitis (NASH) is the second most common cause of the hepatitis. In this study, we aimed to investigate the effects and mechanisms of Cyclocarya paliurus (CPF) flavonoids extract in the treatment of NASH. To achieve this, we performed compound target prediction and network analysis based on the method of network pharmacology. We investigated the effect of CPF extract on NASH and the underlying molecular mechanisms using the in vivo pharmacological evaluation technique. Materials and Methods: First, NASH was induced in mice with a high-fat diet. Furthermore, experimental validation was carried out with a high-fat feed-induced NASH mouse model. Chemical compounds and human target proteins of CPF, as well as NASH-related human genes, were obtained from TCMSP, PubChem, and GenBank Database, respectively. Subsequently, molecular networks and typical pathways presumably involved in the treatment of CPF on NASH were performed by Metoscape and String software. Then, the network was constructed by using Cytoscape v3.7.2. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment was performed by using Database for Annotation. Then, the possible underlying mechanisms were studied using the quantitative reverse transcription polymerase chain reaction and Western blot analysis. Results: The network pharmacology research showed that the CPF, which contained 26 compounds and 27 genes, regulated the most signaling pathways related to NASH. Moreover, the protein–protein interaction network based on the targets of CPF on NASH revealed that the core compounds were luteolin, quercetin, kaempferol, ellagic acid, isoquercitrin, gallic acid, inositol, and myricetin, which were regulated by more than 4 compounds, remarkable related with peroxisome proliferator-activated receptor (PPAR) signaling pathway, cholesterol metabolism, bile secretion, type II diabetes mellitus, adenosine 5′-monophosphate-activated protein kinase signaling pathway, and insulin signaling pathway. In addition, carnitine palmitoyltransferase 2, cytochrome P450 family 7 subfamily A member 1 (CYP7A1), cytochrome P450 family 27 subfamily A member 1 (CYP27A1), and fatty acid-binding protein 1 were treated as target genes of CPF in NASH. In vivo experiments indicated that CPF promoted Peroxisome proliferator-activated receptor alpha (PPAR α)/Peroxisome proliferator-activated receptor gamma (PPAR γ) signaling pathway in NASH mouse model. Conclusion: CPF played a role in inhibiting lipid response in NASH, which was closely associated with the modulation effect of CPF on PPAR α/PPAR γ signaling pathway.

Intralesional corticosteroids in the treatment of nodulocystic acne.

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

Ganoderic Acid A Ameliorates Non-Alcoholic Streatohepatitis (NASH) Induced by High-Fat High-Cholesterol Diet in Mice

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism.

Pyrvinium pamoate ameliorates cyclosporin A- induced hepatotoxicity via the modulation of Wnt/β-catenin signaling and upregulation of PPAR-γ

[A successful repair of recurrent coarctation using a heparinized shunt tube (Anthron)].

Neohesperidin enhances PGC-1α-mediated mitochondrial biogenesis and alleviates hepatic steatosis in high fat diet fed mice

Polyene Phosphatidylcholine Ameliorates High Fat Diet-Induced Non-alcoholic Fatty Liver Disease via Remodeling Metabolism and Inflammation

Effects of cyclocarya paliurus flavonoid extract in non-alcoholic steatohepatitis mice: Intermeshing network pharmacology and in vivo pharmacological evaluation

PGC1 protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response

Piperine alleviates nonalcoholic steatohepatitis by inhibiting NF-κB-mediated hepatocyte pyroptosis

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model

Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation

Raspberry ketone protects rats fed high-fat diets against nonalcoholic steatohepatitis

Hesperidin Protects Against High-Fat Diet-Induced Lipotoxicity in Rats by Inhibiting Pyroptosis

PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat

Intestinal peroxisome proliferator-activated receptor -fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis

PPARβ/δ attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells

Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway

Hepalatide Ameliorated Progression of Nonalcoholic Steatohepatitis in Mice.